Drug intelligence / Profile preview

abatacept + mycophenolate mofetil + corticosteroids

Development stage
Preclinical
Lead developer
Bristol Myers Squibb
Modality
Small Molecules
Administration
Intravenous, Subcutaneous, Oral
01

Overview

This is a **combination therapy** consisting of abatacept (a selective T-cell co-stimulation modulator and fusion protein blocking CD80/CD86 on antigen-presenting cells), mycophenolate mofetil (a small molecule prodrug inhibiting inosine monophosphate dehydrogenase, thus suppressing lymphocyte proliferation), and corticosteroids (a class of steroid hormones with potent anti-inflammatory and immunosuppressive effects). The regimen is an aggressive immunosuppressive approach used in refractory autoimmune and inflammatory conditions (such as juvenile dermatomyositis, lupus nephritis, or immune checkpoint inhibitor-induced inflammatory conditions) when conventional therapy fails. Each component works through a distinct mechanism to synergistically suppress immune activity, targeting T cell activation, lymphocyte proliferation, and broad inflammatory responses[1][2][3][6].

Brand names
Orencia + Cellcept + corticosteroids
Other names
ABA + MMF + corticosteroids
02

Targets

CD80 (T-lymphocyte activation antigen CD80)CD86 (T-lymphocyte activation antigen CD86)GR (Glucocorticoid receptor)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)

Beyond the preview

Go deeper on abatacept + mycophenolate mofetil + corticosteroids.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on abatacept + mycophenolate mofetil + corticosteroids.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call